Komplizierte intraabdominelle Infektionen
G-BA action
discontinuation
2020-09-17
Evidence-checked summary
The G-BA issued a discontinuation on 2020-09-17. The official page states that it took effect as follows: 17.09.2020. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.
This is the latest validated public action attached to this case. It is separate from the IQWiG assessment result.
Official case record
No inferred stages
Consultation record
2020-08-11
130 parsed turns
Oral hearing: Ceftolozan/Tazobactam (Komplizierte intraabdominelle Infektionen)
Official Wortprotokoll · 27 pages
IQWiG comparison
IQWiG assessment findings and the later G-BA action are separate records. Open both to compare them.
A20-27
matched
Ceftolozane/tazobactam (complicated intra-abdominal infections) - Benefit assessment according to §35a Social Code Book V
Official assessment PDF · 45 pages
G-BA decisions
2020-09-17
discontinuation
The G-BA issued a discontinuation on 2020-09-17. The official page states that it took effect as follows: 17.09.2020. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.
2 official documents · 3 cited claims
Official sources